Analyst Reco. Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
9.73 ^USD	-4.33%		+1.88%	+26.69%

05-09	Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-23	HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating	04-23	MT
Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating	03-26	MT
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $30, Maintains Outperform Rating	11-15	MT
Wedbush Trims Astria Therapeutics' Price Target to $17 From $18, Keeps Outperform Rating	11-13	MT
Wedbush Adjusts Price Target on Astria Therapeutics to $18 From $25, Maintains Outperform Rating	13/10/23	MT
HC Wainwright Adjusts Astria Therapeutics Price Target to $18 From $20, Maintains Buy Rating	12/10/23	MT
Wedbush Trims Astria Therapeutics' Price Target to $25 From $26, Keeps Outperform Rating	08/08/23	MT
Evercore ISI Initiates Coverage on Astria Therapeutics With Outperform Rating, $18 Price Target	28/03/23	MT
Wedbush Adjusts Price Target on Astria Therapeutics to $26 From $27, Keeps Outperform Rating	22/03/23	MT
HC Wainwright Adjusts Astria Therapeutics Price Target to $20 From $13, Maintains Buy Rating	19/12/22	MT
Wedbush Adjusts Astria Therapeutics Price Target to $27 From $16, Maintains Outperform Rating	15/12/22	MT
Wedbush Lifts Price Target on Astria Therapeutics to $16 From $15, Keeps Outperform Rating	10/08/22	MT
Wedbush Adjusts Astria Therapeutics' Price Target to $15 From $16, Keeps Outperform Rating	11/11/21	MT
ASTRIA THERAPEUTICS : Jefferies Starts Astria Therapeutics at Buy with $20 Price Target	29/09/21	MT
ASTRIA THERAPEUTICS : Oppenheimer Raises Astria Therapeutics' PT to $30 from $5 After 1 for 6 Reverse Stock Split, Keeps Outperform Rating	24/09/21	MT
CATABASIS PHARMACEUTICALS : Wedbush Initiates Catabasis Pharmaceuticals at Outperform Rating With $16 Price Target	02/09/21	MT
CATABASIS PHARMACEUTICALS : HC Wainwright Upgrades Catabasis Pharmaceuticals to Buy From Neutral; Price Target is $13	25/08/21	MT
CATABASIS PHARMACEUTICALS : Ladenburg Thalmann Starts Catabasis Pharmaceuticals at Buy With $6 Price Target	12/05/21	MT
CATABASIS PHARMACEUTICALS : Oppenheimer Upgrades Catabasis Pharmaceuticals to Outperform From Perform, $5 Price Target	11/03/21	MT
CATABASIS PHARMACEUTICALS : Oppenheimer Upgrades Catabasis Pharmaceuticals to Outperform from Perform, Sets $5 Price Target	11/03/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Analyst Reco.

Filters